The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CLENTIAZEM     [(4R,5R)-9-chloro-2-(2- dimethylaminoethyl)...

Synonyms: Clentiazemum, SureCN33909, CHEMBL348763, CHEBI:375076, LS-178284, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of CLENTIAZEM


High impact information on CLENTIAZEM


Chemical compound and disease context of CLENTIAZEM


Biological context of CLENTIAZEM


Anatomical context of CLENTIAZEM

  • Also, neutrophil accumulation at the epicardial side of the infarct, at the edge of salvaged myocardium, and estimated by tissue myeloperoxidase measurement, was reduced by 50% in treated dogs (clentiazem: 17.2 +/- 2.8; controls: 32.3 +/- 2.7 x 10(6) neutrophils/g) [13].
  • 1. We examined the mechanisms underlying Ca2+-induced relaxation in the presence of clentiazem, a new Ca2+-antagonist, in depolarized coronary arteries of the dog [14].
  • The postischemic cardioprotection by calcium antagonists and the interplay between neutrophils and regional myocardial blood flow were investigated further, using clentiazem, a new potent calcium channel blocker derived from diltiazem [13].
  • Azidobutyryl clentiazem, a new photoactivatable diltiazem analog, labels benzothiazepine binding sites in the alpha 1 subunit of the skeletal muscle calcium channel [15].
  • 2. Ca2+ (3 x 10(-5)-3 x 10(-3) M) caused an unexpected relaxation in the presence of a high concentration of clentiazem (10(-6) M) in coronary, but not in mesenteric or renal arteries [14].

Associations of CLENTIAZEM with other chemical compounds


Gene context of CLENTIAZEM

  • PDGF-induced prolifertion of these cells is markedly inhibited by clentiazem [10].
  • The aortas of the clentiazem groups demonstrated significantly less ORO staining than CCT diet controls in thoracic aorta after 6 weeks and abdominal aorta after 12 weeks [20].
  • To better characterize the reduced coronary sensitivity to clentiazem in the presence of heart failure, the contributions of the NO synthase and the cyclooxygenase pathways were evaluated [21].
  • Diltiazem, clentiazem and their acidic and basic metabolites extractable with tert-butyl methyl ether, which are all 2,3,5-trisubstituted-1,5-benzothiazepines, were analysed by positive ion electron ionization (PIEI) mass spectrometry, and the structures of fragment ions and their fragmentation pathways were investigated [22].
  • Pretreatment with the Ca channel blocker clentiazem (10(-7) mol/L) itself depressed developed pressure by 53+/-9% [23].

Analytical, diagnostic and therapeutic context of CLENTIAZEM

  • After washout and a 1-week placebo run-in period, patients received 20, 40, 80 or 120 mg/day of clentiazem tablets or placebo as a twice-daily dosage for 1 week of treatment after 1 week of dose titration [1].
  • However, after an initial recovery to preocclusion values at 30-min reperfusion in both groups, flow declined to 50% normal (P < .05) in control animals after 3 and 6 hr in midwall and subendocardium, but the change was remarkably attenuated (P < .05) in subendocardium of clentiazem-treated dogs [13].
  • One group was given clentiazem: 100 micrograms/kg at 5 min before reperfusion followed by a perfusion of 1 microgram/kg/min until sacrifice; controls received saline [13].
  • Pharmacokinetics of clentiazem after intravenous and oral administration in healthy subjects [24].
  • We therefore evaluated the cardioprotective interaction of diltiazem, clentiazem, and cold cardioplegia in both normal and failing ischemic hearts [8].


  1. A dose-response study of clentiazem, a chloro-derivative of diltiazem, in patients with stable angina. CAMCAT Study Group. Waters, D., Garceau, D. J. Am. Coll. Cardiol. (1993) [Pubmed]
  2. Effects of clentiazem on cerebral ischemia induced by carotid artery occlusion in stroke-prone spontaneously hypertensive rats. Kikkawa, K., Yamauchi, R., Suzuki, T., Banno, K., Murata, S., Tetsuka, T., Nagao, T. Stroke (1994) [Pubmed]
  3. The effect of a new calcium antagonist, TA3090 (clentiazem), on experimental transient focal cerebral ischemia in cats. Sakaki, T., Tsujimoto, S., Sasaoka, Y., Tsunoda, S., Shintomi, K. Stroke (1993) [Pubmed]
  4. Clentiazem protects against chronic cerebral vasospasm in rabbit basilar artery. Vorkapic, P., Bevan, J.A., Bevan, R.D. Stroke (1991) [Pubmed]
  5. Inhibition of PDGF-mediated proliferation of vascular smooth muscle cells by calcium antagonists. Kataoka, S., Alam, R., Dash, P.K., Yatsu, F.M. Stroke (1997) [Pubmed]
  6. Clentiazem reduces infarct size in rabbit middle cerebral artery occlusion. Kaminow, L., Bevan, J. Stroke (1991) [Pubmed]
  7. Protective effect of clentiazem against epinephrine-induced cardiac injury in rats. Deisher, T.A., Narita, H., Zera, P., Ginsburg, R., Bristow, M.R., Billingham, M.E., Fowler, M.B., Hoffman, B.B. J. Pharmacol. Exp. Ther. (1993) [Pubmed]
  8. Resistance of the failing dystrophic hamster heart to the cardioprotective effects of diltiazem and clentiazem: evidence of coronary vascular dysfunctions. Tanguay, M., Jasmin, G., Blaise, G., Dumont, L. Can. J. Physiol. Pharmacol. (1995) [Pubmed]
  9. Analysis of the daily variation in blood pressure and pharmacokinetics after single or repeated administration of clentiazem to patients with essential hypertension. Suzuki, S., Mori, M., Kusano, S. Arzneimittel-Forschung. (1992) [Pubmed]
  10. Inhibition of vascular smooth muscle cell proliferation by the calcium antagonist clentiazem: role of protein kinase C. Alam, R., Kataoka, S., Alam, S., Yatsu, F. Atherosclerosis (1996) [Pubmed]
  11. Effect of clentiazem on arterial pressure and renal function in normotensive and hypertensive rats. Fenoy, F.J., Milicic, I., Mistry, M., Mecca, T.E., Roman, R.J. J. Pharmacol. Exp. Ther. (1992) [Pubmed]
  12. Single and multiple oral dose pharmacokinetics of clentiazem in normal volunteers. Bhargava, V.O., Shah, A.K., Weir, S.J., Nordbrock, E.E., Giesing, D.H. Journal of clinical pharmacology. (1993) [Pubmed]
  13. Clentiazem given at reperfusion improves subendocardial reflow and reduces myocardial infarct size in the dog. Rousseau, G., Provost, P., Tran, D., Caillé, G., Latour, J.G. J. Pharmacol. Exp. Ther. (1994) [Pubmed]
  14. Endothelium-dependent calcium-induced relaxation in the presence of Ca2+-antagonists in canine depolarized coronary arteries. Kikkawa, K., Murata, S., Nagao, T. Br. J. Pharmacol. (1989) [Pubmed]
  15. Azidobutyryl clentiazem, a new photoactivatable diltiazem analog, labels benzothiazepine binding sites in the alpha 1 subunit of the skeletal muscle calcium channel. Watanabe, T., Kalasz, H., Yabana, H., Kuniyasu, A., Mershon, J., Itagaki, K., Vaghy, P.L., Naito, K., Nakayama, H., Schwartz, A. FEBS Lett. (1993) [Pubmed]
  16. Immunosuppressive properties of the benzothiazepine calcium antagonists diltiazem and clentiazem, with and without cyclosporine, in heterotopic rat heart transplantation. Dumont, L., Chen, H., Daloze, P., Xu, D., Garceau, D. Transplantation (1993) [Pubmed]
  17. Hemodynamic and metabolic effects of intravenous clentiazem in hypertensive patients. Frohlich, E.D., McLoughlin, M., Ketelhut, R. Am. J. Cardiol. (1992) [Pubmed]
  18. Binding characteristics of a new 1,5-benzothiazepine, clentiazem, to rat cerebral cortex and skeletal muscle membranes. Suzuki, T., Kurosawa, H., Naito, K., Otsuka, M., Ohashi, M., Takaiti, O. Eur. J. Pharmacol. (1991) [Pubmed]
  19. Antianginal effect of RS-5773, a diltiazem congener, in the methacholine-induced anginal model in rats. Shiga, H., Miyake, S., Fukuda, N., Yorikane, R., Koike, H. Jpn. J. Pharmacol. (1996) [Pubmed]
  20. Inhibition of lipid deposition in the hypercholesterolemic rat by clentiazem, a calcium channel blocker. Nunnari, J.J., Fisher, M., White, S.D. Exp. Mol. Pathol. (1992) [Pubmed]
  21. Coronary and cardiac sensitivity to the vasoselective benzothiazepine-like calcium antagonist, clentiazem, in experimental heart failure. Tanguay, M., Jasmin, G., Blaise, G., Dumont, L. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. (1997) [Pubmed]
  22. Positive ion EI mass spectra of 2,3,5-trisubstituted-1,5-benzothiazepines, diltiazem, clentiazem and their fat-soluble metabolites. Sugawara, Y., Nakamura, S. Journal of pharmaceutical and biomedical analysis. (1994) [Pubmed]
  23. Mechanism for the cardioprotective effects of the calcium channel blocker clentiazem during ischemia and reperfusion. Kusuoka, H., Corretti, M.C., Koretsune, Y., Marban, E. Jpn. Circ. J. (1998) [Pubmed]
  24. Pharmacokinetics of clentiazem after intravenous and oral administration in healthy subjects. Shah, A.K., Bhargava, V.O., Weir, S.J., Giesing, D.H. Journal of clinical pharmacology. (1993) [Pubmed]
WikiGenes - Universities